|

UTAA17 Injection Clinical Trials

1 actively recruiting trial

Also known as: Chimeric antigen receptor modified T cell injections targeting BCMA

Top Sponsors

  • PersonGen BioTherapeutics (Suzhou) Co., Ltd.1

Indications

  • Relapsed/ Refractory Multiple Myeloma1
  • Cancer1

Other1 trial

UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.